Literature DB >> 30348496

Inactive Atm abrogates DSB repair in mouse cerebellum more than does Atm loss, without causing a neurological phenotype.

Efrat Tal1, Marina Alfo1, Shan Zha2, Ari Barzilai3, Chris I De Zeeuw4, Yael Ziv1, Yosef Shiloh5.   

Abstract

The genome instability syndrome, ataxia-telangiectasia (A-T) is caused by null mutations in the ATM gene, that lead to complete loss or inactivation of the gene's product, the ATM protein kinase. ATM is the primary mobilizer of the cellular response to DNA double-strand breaks (DSBs) - a broad signaling network in which many components are ATM targets. The major clinical feature of A-T is cerebellar atrophy, characterized by relentless loss of Purkinje and granule cells. In Atm-knockout (Atm-KO) mice, complete loss of Atm leads to a very mild neurological phenotype, suggesting that Atm loss is not sufficient to markedly abrogate cerebellar structure and function in this organism. Expression of inactive ("kinase-dead") Atm (AtmKD) in mice leads to embryonic lethality, raising the question of whether conditional expression of AtmKD in the murine nervous system would lead to a more pronounced neurological phenotype than Atm loss. We generated two mouse strains in which AtmKD was conditionally expressed as the sole Atm species: one in the CNS and one specifically in Purkinje cells. Focusing our analysis on Purkinje cells, the dynamics of DSB readouts indicated that DSB repair was delayed longer in the presence of AtmKD compared to Atm loss. However, both strains exhibited normal life span and displayed no gross cerebellar histological abnormalities or significant neurological phenotype. We conclude that the presence of AtmKD is indeed more harmful to DSB repair than Atm loss, but the murine central nervous system can reasonably tolerate the extent of this DSB repair impairment. Greater pressure needs to be exerted on genome stability to obtain a mouse model that recapitulates the severe A-T neurological phenotype.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ATM; Ataxia-telangiectasia; Cerebellar atrophy; DNA damage response; Double-strand breaks; Kinase-dead

Mesh:

Substances:

Year:  2018        PMID: 30348496     DOI: 10.1016/j.dnarep.2018.10.001

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  5 in total

1.  The Cancer-Associated ATM R3008H Mutation Reveals the Link between ATM Activation and Its Exchange.

Authors:  Maja Milanovic; Lisa M Houghton; Demis Menolfi; Ji-Hoon Lee; Kenta Yamamoto; Yang Li; Brian J Lee; Jun Xu; Verna M Estes; Dong Wang; Peter J Mckinnon; Tanya T Paull; Shan Zha
Journal:  Cancer Res       Date:  2020-11-25       Impact factor: 12.701

2.  A novel, ataxic mouse model of ataxia telangiectasia caused by a clinically relevant nonsense mutation.

Authors:  Harvey Perez; May F Abdallah; Jose I Chavira; Angelina S Norris; Martin T Egeland; Karen L Vo; Callan L Buechsenschuetz; Valentina Sanghez; Jeannie L Kim; Molly Pind; Kotoka Nakamura; Geoffrey G Hicks; Richard A Gatti; Joaquin Madrenas; Michelina Iacovino; Peter J McKinnon; Paul J Mathews
Journal:  Elife       Date:  2021-11-01       Impact factor: 8.713

3.  Persistent DNA damage associated with ATM kinase deficiency promotes microglial dysfunction.

Authors:  Julie Bourseguin; Wen Cheng; Emily Talbot; Liana Hardy; Jenny Lai; Ailsa M Jeffries; Michael A Lodato; Eunjung Alice Lee; Svetlana V Khoronenkova
Journal:  Nucleic Acids Res       Date:  2022-03-21       Impact factor: 16.971

4.  The Essential DNA Damage Response Complex MRN Is Dispensable for the Survival and Function of Purkinje Neurons.

Authors:  Mingmei Ding; Xiaobing Qing; Guangyu Zhang; Carolin Baade-Büttner; Ralph Gruber; Haizhen Lu; David O Ferguson; Christian Geis; Zhao-Qi Wang; Zhong-Wei Zhou
Journal:  Front Aging Neurosci       Date:  2022-01-28       Impact factor: 5.750

Review 5.  Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease.

Authors:  Gwyneth Welch; Li-Huei Tsai
Journal:  EMBO Rep       Date:  2022-05-02       Impact factor: 9.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.